ClinicalTrials.gg
CompletedNCT04468776COZIUpdated Feb 24, 2025Results posted

CBT-I or Zolpidem/Trazodone for Insomnia

A Phase 4 interventional study of Zolpidem and Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) in Chronic Insomnia, sponsored by California Pacific Medical Center Research Institute. Completed at 7 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by California Pacific Medical Center Research Institute · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders — 2 open to participants now, 2 under way, 1 of them phase 3. Zolpidem · Sleep Initiation and Maintenance Disorders.

Enrollment
11th of 40
155 · median 108
Started
2022
the only one that year
Phase 4
19 of 40
1 open now
Registered
37th of 40
by date
Lead sponsor
1 of 40
California Pacific Medical Center Research Institute

Among the 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders, this one is the 11th largest by enrollment, is the only one that started in 2022, is one of 19 in phase 4, and was the 37th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

2 of the 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About zolpidem

Zolpidem: first FDA approval 1992 (AMBIEN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing zolpidem in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

This study is a randomized (1:1:1) comparative effectiveness trial of medication (zolpidem or trazodone), cognitive-behavioral therapy for insomnia (CBT-I), and the combination (medication + CBT-I) for the treatment of chronic insomnia in men and women aged 18-80 living in rural areas with 1 year of follow-up. A total of 155 participants will be enrolled and randomized in the United States. This trial is funded by the Patient-Centered Outcomes Research Institute.

Read the detailed description

Insomnia is a common health problem that causes distress, impaired function, and increased risk for other health problems. Chronic insomnia is defined by problems with the quality or amount of sleep, including difficulty falling asleep, frequent awakenings, and/or awakening early and being unable to return to sleep. In developing this application, patients, providers, payors, and the investigators identified both concerns and opportunities with current treatments for chronic insomnia. Medications and Cognitive-Behavioral therapy for insomnia (CBT-I; a treatment program to improve sleep through changes in behavior and thinking) are both effective for treating insomnia. Zolpidem, the most frequently prescribed insomnia medication, is widely available, but may cause side effects and dependency. Trazodone is increasingly prescribed off-label for treatment of insomnia, but evidence of efficacy and safety is more limited. CBT-I is the recommended first line treatment by many professional organizations, but it is not widely available in physicians' practices. Patients, providers, and payors face important unanswered questions: Which treatment should be used for the treatment of chronic insomnia? Is combination therapy more effective, and does it result in lower zolpidem use? Who responds best to which treatment? These dilemmas are particularly relevant to patients and providers in rural areas, where access to behavioral health specialists is limited, and concerns regarding use of controlled substances is particularly acute.

To address these questions, we propose the study, Comparative Effectiveness of Zolpidem/Trazodone and Cognitive Behavioral Therapy for Insomnia in Rural Adults (COZI). The investigators will use a well-tested Internet version of CBT-I, which is just as effective as in-person CBT-I, but more widely available. The aims of COZI are to: 1: Compare the effectiveness of medication preference (zolpidem or trazodone), CBT-I, and combination treatment for insomnia symptoms over 6 months. 2: Compare the effectiveness of medication preference, CBT-I, and combination treatment for other symptoms and problems, including health-related quality of life, mood, and health outcomes. 3: Compare the side effects of medication preference, CBT-I, and combination treatment. COZI will study 155 patients recruited from 7 health care systems across the country, each of which has established practices in rural areas. Patients will be treated with medication prescribed by their own physician (zolpidem or trazodone), Internet CBT-I, or a combination of the two. The investigators will evaluate treatment effects at 9 weeks, and 6 and 12 months (with limited additional assessments for adverse events and medication use at 1 and 9 months). Our study questions and design reflect early and ongoing engagement of key stakeholders including patients, providers, and payors, who are members of the Study Advisory Committee (SAC). SAC members will work with study investigators to recommend the best strategies for recruiting patients, measuring treatment effects, and disseminating study findings. The SAC will meet quarterly. Patients and other stakeholders have already provided guidance on which treatments are most worth studying, and which symptoms would best reflect the effects of treatment. Patients and other stakeholders will also be part of the Steering Committee, which is the main decision-making group for our study, and which will meet monthly. COZI will lead to answers for patients and providers addressing insomnia; improved health and function for millions of rural Americans; and sustainable changes in how insomnia is treated in rural practices.

03

Conditions studied

  • Chronic Insomnia

Keywords

  • Insomnia
  • Chronic Insomnia
  • Zolpidem
  • Ambien
  • Cognitive-behavioral therapy for insomnia
  • CBT-I
  • Rural
  • Primary Care
  • Pragmatic Clinical Trial
  • Comparative Effectiveness
  • Trazodone
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80
  • Insomnia Severity Index score > 10
  • Regular internet and computer access
  • Receives primary care in a Non-metropolitan/Rural residence

Exclusion criteria

Exclusion Criteria:

  • Use of hypnotic medication >2 times in the past week
  • Current cognitive or cognitive behavioral treatment for insomnia
  • Psychotic disorder
  • Bipolar disorder
  • Current substance use disorder
  • Severe (COPD) or other severe pulmonary disease (such as asthma or lung fibrosis)
  • Cognitive impairment or dementia
  • History of spontaneous or hypnotic-induced complex sleep behavior
  • Delayed sleep phase disorder (DSPD)
  • Shift work that includes working the night shift (between the hours of 12:00 a.m. - 6:00 a.m.)
  • History of fracture or injurious fall in the past 12 months
  • Currently pregnant, planning to become pregnant, or breastfeeding
  • Other severe or uncontrolled mental or physical disorders that would make participation difficult or unsafe
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
155 participants (actual)

Study arms

  • Active comparator
    Medication (zolpidem or trazodone)

    Zolpidem or trazodone, as prescribed by physician

    Drug: Zolpidem · Drug: Trazodone

  • Active comparator
    Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)

    Internet-based CBT-I program

    Behavioral: Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)

  • Experimental
    Combination

    Medication (zolpidem or trazodone) as prescribed by physician and Internet-based CBT-I program

    Drug: Zolpidem · Behavioral: Internet Cognitive Behavioral Therapy for Insomnia (CBT-I) · Drug: Trazodone

Interventions

  • Zolpidem, as prescribed by physician

    Also known as: Ambien

  • BehavioralInternet Cognitive Behavioral Therapy for Insomnia (CBT-I)

    6-week internet CBT-I multi-component intervention (SHUTi) including sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention

    Also known as: SHUTi

  • Trazodone, as prescribed by physician

    Also known as: Desyrel

06

What researchers measure

Primary outcomes

  1. Change in Insomnia Symptom Severity

    Change in Insomnia Severity Index score from baseline to follow-up. The Insomnia Severity Index is a 7-item self-report questionnaire that measures severity of insomnia symptoms during the last two weeks. Each item is scored 0 (no problem) to 4 (very severe problem) and total between 0-28, with higher scores indicating more severe insomnia symptoms. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Baseline ISI, Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.

    Time frame: Baseline, 6 months

Secondary outcomes

  1. Number of Participants With Treatment Response of Insomnia Symptoms

    Treatment response defined as a ≥6 point reduction in Insomnia Severity Index score from baseline to follow-up. The Insomnia Severity Index is a 7-item self-report questionnaire that measures severity of insomnia symptoms during the last two weeks. Each item is scored 0 (no problem) to 4 (very severe problem) and total between 0-28, with higher scores indicating more severe insomnia symptoms. Data presented as count of participants meeting treatment response criteria at 6 months.

    Time frame: Baseline, 6 months

  2. Number of Participants With Remission of Insomnia Symptoms

    Remission of Insomnia symptoms defined as Insomnia Severity Index \<8 at follow-up. The Insomnia Severity Index is a 7-item self-report questionnaire that measures severity of insomnia symptoms during the last two weeks. Each item is scored 0 (no problem) to 4 (very severe problem) and total between 0-28, with higher scores indicating more severe insomnia symptoms. Data presented as count of participants meeting insomnia remission criteria at 6 months.

    Time frame: 6 months

Other outcomes

  1. Change in Anxiety and Depression

    The Patient Health Questionnaire (PHQ-8) is an 8-item self-report measure for assessing depression severity. The items are summed to yield a score between 0 and 24, with higher scores indicating more frequent depression symptoms. The Generalized Anxiety Disorder (GAD-7) Scale is a 7-item self-report measure used for screening and assessing severity of GAD. The items are summed to yield a score between 0 and 21, with higher scores indicating more severe GAD symptoms. Change is estimated mean change in mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.

    Time frame: Baseline, 6 months

  2. Change in Cognitive Function

    The PROMIS Cognitive Function Short Form (8a) is an 8-item self-report measure related to executive functioning. Individual item responses range from 1 (very often) to 5 (never) and the total raw score is converted to standardized T-scores using established United States general adult population with a mean of 50 and a standard deviation of 10. Higher T-scores signify better cognitive function. Estimated mean change in T-score from baseline to follow-up is reported from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site. Positive change indicates improved cognitive function.

    Time frame: Baseline, 6 months

  3. Change in Patient-Reported Health

    The PROMIS Global Health is a 10-item self-report measure that assess general health and functioning. Item responses range from 1 (excellent/none) to 5 (poor/always) and a single pain item ranges from 0 (no pain) to 10 (worst pain). Physical and mental health sub-scores are calculated from 4 items each, and the total raw sub-scores (range: 4-20) are converted to T-scores using distributions standardized to mean 50 (SD 10) for the US general population. Higher score indicates greater health-related quality of life. The Medical Outcome Survey (SF-12) is a 12-item self-report measure of physical and mental health. The Physical Component Score (PCS) and Mental Component Score (MCS) sub-scores range 0-100; higher score indicates better health. Change is estimated mean change from baseline to follow-up in mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.

    Time frame: Baseline, 6 months

  4. Change in Fatigue

    The PROMIS Fatigue instrument is a 7-item self-report measure that assesses recent fatigue and how fatigue interfered with daily activities. Scores range from 7 to 35, with higher scores indicating greater fatigue. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.

    Time frame: Baseline, 6 months

  5. Change in Pain Intensity and Interference

    The PROMIS Pain Intensity scale is a 3-item instrument used to assess how much pain a person has. Scores range from 3-15, with higher scores indicating greater pain intensity. The PROMIS Pain Interference scale is a 6-item instrument used to assess the consequences of pain in different domains of daily life. Scores range from 6-30, with higher scores indicating greater interference. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.

    Time frame: Baseline, 6 months

  6. Change in Pittsburgh Sleep Quality Index

    The Pittsburgh Sleep Quality Index (PSQI) is an 18-item self-report measure that assesses sleep quality in the past month. These items are combined into seven component scores (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleep medication, and daytime dysfunction). The seven component scores are added to produce a global sleep quality score ranging from 0 to 21; higher total score indicates worse sleep quality. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.

    Time frame: Baseline, 6 months

  7. Change in Daytime Sleepiness

    The Epworth Sleepiness Scale (ESS) is an 8-item self-report measure that assesses daytime sleepiness by asking about the likelihood of dozing in certain situations. Individual items are summed to yield the ESS score between 0 (never doze) to 24 (doze a lot) with higher scores indicating more sleepiness. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.

    Time frame: Baseline, 6 months

  8. Change in Munich Chronotype

    The Munich Chronotype Questionnaire (MCTQ) is a self-report scale to assess sleep structure, patterns, duration, and quality. The chronotype sub-score represents the mid-point time of sleep which is converted to a numeric value by adding the hour plus minutes divided by 60. Greater values indicate later chronotype. Positive change values indicate a shift to later chronotype. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.

    Time frame: Baseline, 6 months

  9. Dysfunctional Beliefs and Attitudes About Sleep

    Dysfunctional Beliefs and Attitudes about Sleep (DBAS) Scale is a 16-item instrument used to evaluate dysfunctional thoughts related to insomnia. Each item is scored 0-10 and the total is the average of the 16 item scores (range 0-10), with higher scores indicating greater dysfunctional beliefs about sleep.

    Time frame: Baseline, 6 months

  10. Number of Participants With Insomnia Treatment Side Effects

    Side effects (frequency, severity, impairment) are recorded via self-report adapted from the FIBSER. Scores range from 0 (no side effects; better) to 21 (worse). Side effects were analyzed if participant reported severity of greater than moderate and/or frequency greater than 50% of the time. Count of participants meeting the threshold for analysis up through the 6 month follow-up.

    Time frame: 1 month, 9 weeks, 6 months

  11. Medication Adherence

    Medication use is assessed using self-reported prescription, over-the-counter, and supplement name and frequency. Count of participants reporting zolpidem or trazodone use for sleep is recorded for adherence to the Medication and Combination treatment arms.

    Time frame: 1 month, 9 weeks, 6 months, 9 months, 12 months

  12. Self-reported Falls

    Participants self-reported number of falls including context, location, and consequences of falls. Count of participants with one or more falls up through the 6 month follow-up.

    Time frame: 1 month, 9 weeks, 6 months

07

Results

Posted Feb 24, 2025

Participant flow

Participant flow — Overall Study
MilestoneMedication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)Combination
Started495452
9 weeks follow-up403741
6 months follow-up383234
12 months follow-up373033
Completed444043
Not completed5149
Withdrew: Lost to follow-up434
Withdrew: Withdrawal by subject1104
Withdrew: Physician decision011

Outcome measures

PrimaryChange in Insomnia Symptom Severity

Change in Insomnia Severity Index score from baseline to follow-up. The Insomnia Severity Index is a 7-item self-report questionnaire that measures severity of insomnia symptoms during the last two weeks. Each item is scored 0 (no problem) to 4 (very severe problem) and total between 0-28, with higher scores indicating more severe insomnia symptoms. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Baseline ISI, Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.

Time frame:
Baseline, 6 months
Reported as:
Least squares mean · change score on a scale
Change in Insomnia Symptom Severity
change score on a scaleMedication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)Combination
Change in Insomnia Symptom Severity-8.05 (-9.44 to -6.65)-7.82 (-9.32 to -6.32)-10.19 (-11.66 to -8.73)
SecondaryNumber of Participants With Treatment Response of Insomnia Symptoms

Treatment response defined as a ≥6 point reduction in Insomnia Severity Index score from baseline to follow-up. The Insomnia Severity Index is a 7-item self-report questionnaire that measures severity of insomnia symptoms during the last two weeks. Each item is scored 0 (no problem) to 4 (very severe problem) and total between 0-28, with higher scores indicating more severe insomnia symptoms. Data presented as count of participants meeting treatment response criteria at 6 months.

Time frame:
Baseline, 6 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Response of Insomnia Symptoms
ParticipantsMedication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)Combination
Number of Participants With Treatment Response of Insomnia Symptoms222131
SecondaryNumber of Participants With Remission of Insomnia Symptoms

Remission of Insomnia symptoms defined as Insomnia Severity Index \<8 at follow-up. The Insomnia Severity Index is a 7-item self-report questionnaire that measures severity of insomnia symptoms during the last two weeks. Each item is scored 0 (no problem) to 4 (very severe problem) and total between 0-28, with higher scores indicating more severe insomnia symptoms. Data presented as count of participants meeting insomnia remission criteria at 6 months.

Time frame:
6 months
Reported as:
Count of participants · Participants
Number of Participants With Remission of Insomnia Symptoms
ParticipantsMedication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)Combination
Number of Participants With Remission of Insomnia Symptoms161316
Other pre-specifiedChange in Anxiety and Depression

The Patient Health Questionnaire (PHQ-8) is an 8-item self-report measure for assessing depression severity. The items are summed to yield a score between 0 and 24, with higher scores indicating more frequent depression symptoms. The Generalized Anxiety Disorder (GAD-7) Scale is a 7-item self-report measure used for screening and assessing severity of GAD. The items are summed to yield a score between 0 and 21, with higher scores indicating more severe GAD symptoms. Change is estimated mean change in mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.

Time frame:
Baseline, 6 months
Reported as:
Least squares mean · change score on a scale
Change in Anxiety and Depression
change score on a scaleMedication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)Combination
Patient Health Questionnaire (PHQ-8)-2.37 (-3.39 to -1.36)-2.74 (-3.87 to -1.61)-4.63 (-5.7 to -3.56)
Generalized Anxiety Disorder (GAD-7)-1.24 (-2.26 to -0.23)-2.16 (-3.29 to -1.03)-2.34 (-3.4 to -1.27)
Other pre-specifiedChange in Cognitive Function

The PROMIS Cognitive Function Short Form (8a) is an 8-item self-report measure related to executive functioning. Individual item responses range from 1 (very often) to 5 (never) and the total raw score is converted to standardized T-scores using established United States general adult population with a mean of 50 and a standard deviation of 10. Higher T-scores signify better cognitive function. Estimated mean change in T-score from baseline to follow-up is reported from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site. Positive change indicates improved cognitive function.

Time frame:
Baseline, 6 months
Reported as:
Least squares mean · T-score
Change in Cognitive Function
T-scoreMedication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)Combination
Change in Cognitive Function2.87 (0.81 to 4.93)6.64 (4.36 to 8.93)4.58 (2.42 to 6.74)
Other pre-specifiedChange in Patient-Reported Health

The PROMIS Global Health is a 10-item self-report measure that assess general health and functioning. Item responses range from 1 (excellent/none) to 5 (poor/always) and a single pain item ranges from 0 (no pain) to 10 (worst pain). Physical and mental health sub-scores are calculated from 4 items each, and the total raw sub-scores (range: 4-20) are converted to T-scores using distributions standardized to mean 50 (SD 10) for the US general population. Higher score indicates greater health-related quality of life. The Medical Outcome Survey (SF-12) is a 12-item self-report measure of physical and mental health. The Physical Component Score (PCS) and Mental Component Score (MCS) sub-scores range 0-100; higher score indicates better health. Change is estimated mean change from baseline to follow-up in mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.

Time frame:
Baseline, 6 months
Reported as:
Least squares mean · change score on a scale
Change in Patient-Reported Health
change score on a scaleMedication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)Combination
Global Health: Mental1.22 (-0.52 to 2.95)2.43 (0.49 to 4.37)4.01 (2.18 to 5.83)
Global Health: Physical2.87 (1.22 to 4.52)2.51 (0.68 to 4.35)3.59 (1.86 to 5.32)
SF-12 Physical Component Score2.92 (0.75 to 5.09)0.07 (-2.33 to 2.46)1.92 (-0.34 to 4.18)
SF-12 Mental Component Score-0.11 (-2.85 to 2.63)4.39 (1.38 to 7.4)4.46 (1.61 to 7.3)
Other pre-specifiedChange in Fatigue

The PROMIS Fatigue instrument is a 7-item self-report measure that assesses recent fatigue and how fatigue interfered with daily activities. Scores range from 7 to 35, with higher scores indicating greater fatigue. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.

Time frame:
Baseline, 6 months
Reported as:
Least squares mean · change score on a scale
Change in Fatigue
change score on a scaleMedication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)Combination
Change in Fatigue-5.44 (-7.99 to -2.89)-8.82 (-11.66 to -5.99)-6.8 (-9.48 to -4.12)
Other pre-specifiedChange in Pain Intensity and Interference

The PROMIS Pain Intensity scale is a 3-item instrument used to assess how much pain a person has. Scores range from 3-15, with higher scores indicating greater pain intensity. The PROMIS Pain Interference scale is a 6-item instrument used to assess the consequences of pain in different domains of daily life. Scores range from 6-30, with higher scores indicating greater interference. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.

Time frame:
Baseline, 6 months
Reported as:
Least squares mean · change score on a scale
Change in Pain Intensity and Interference
change score on a scaleMedication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)Combination
Pain Intensity-0.55 (-2.7 to 1.6)-1.72 (-4.13 to 0.68)-3.84 (-6.11 to -1.58)
Pain Interference-1.81 (-4.26 to 0.63)0.72 (-2.01 to 3.44)-3.73 (-6.3 to -1.16)
Other pre-specifiedChange in Pittsburgh Sleep Quality Index

The Pittsburgh Sleep Quality Index (PSQI) is an 18-item self-report measure that assesses sleep quality in the past month. These items are combined into seven component scores (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleep medication, and daytime dysfunction). The seven component scores are added to produce a global sleep quality score ranging from 0 to 21; higher total score indicates worse sleep quality. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.

Time frame:
Baseline, 6 months
Reported as:
Least squares mean · change score on a scale
Change in Pittsburgh Sleep Quality Index
change score on a scaleMedication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)Combination
Change in Pittsburgh Sleep Quality Index-3.42 (-4.46 to -2.38)-4.52 (-5.67 to -3.37)-5.23 (-6.32 to -4.15)
Other pre-specifiedChange in Daytime Sleepiness

The Epworth Sleepiness Scale (ESS) is an 8-item self-report measure that assesses daytime sleepiness by asking about the likelihood of dozing in certain situations. Individual items are summed to yield the ESS score between 0 (never doze) to 24 (doze a lot) with higher scores indicating more sleepiness. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.

Time frame:
Baseline, 6 months
Reported as:
Least squares mean · change score on a scale
Change in Daytime Sleepiness
change score on a scaleMedication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)Combination
Change in Daytime Sleepiness-2.81 (-3.77 to -1.84)-2.61 (-3.68 to -1.54)-2.18 (-3.2 to -1.17)
Other pre-specifiedChange in Munich Chronotype

The Munich Chronotype Questionnaire (MCTQ) is a self-report scale to assess sleep structure, patterns, duration, and quality. The chronotype sub-score represents the mid-point time of sleep which is converted to a numeric value by adding the hour plus minutes divided by 60. Greater values indicate later chronotype. Positive change values indicate a shift to later chronotype. Change is estimated mean change from mixed-effects linear regression model. Fixed effects: Treatment Arm, Visit and Treatment Arm\*Visit interaction. Random effects: intercept for Subject, nested within Site.

Time frame:
Baseline, 6 months
Reported as:
Least squares mean · hours
Change in Munich Chronotype
hoursMedication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)Combination
Change in Munich Chronotype0.08 (-0.16 to 0.33)-0.02 (-.029 to 0.24)0.23 (-0.03 to 0.5)
Other pre-specifiedDysfunctional Beliefs and Attitudes About Sleep

Dysfunctional Beliefs and Attitudes about Sleep (DBAS) Scale is a 16-item instrument used to evaluate dysfunctional thoughts related to insomnia. Each item is scored 0-10 and the total is the average of the 16 item scores (range 0-10), with higher scores indicating greater dysfunctional beliefs about sleep.

Time frame:
Baseline, 6 months
Reported as:
Mean · score on a scale
Dysfunctional Beliefs and Attitudes About Sleep
score on a scaleMedication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)Combination
Baseline DBAS mean total score6.1 ± 1.86.0 ± 1.36.2 ± 1.7
6 months DBAS mean total score5.4 ± 1.84.2 ± 1.64.0 ± 2.1
Other pre-specifiedNumber of Participants With Insomnia Treatment Side Effects

Side effects (frequency, severity, impairment) are recorded via self-report adapted from the FIBSER. Scores range from 0 (no side effects; better) to 21 (worse). Side effects were analyzed if participant reported severity of greater than moderate and/or frequency greater than 50% of the time. Count of participants meeting the threshold for analysis up through the 6 month follow-up.

Time frame:
1 month, 9 weeks, 6 months
Reported as:
Count of participants · Participants
Number of Participants With Insomnia Treatment Side Effects
ParticipantsMedication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)Combination
Number of Participants With Insomnia Treatment Side Effects161315
Other pre-specifiedMedication Adherence

Medication use is assessed using self-reported prescription, over-the-counter, and supplement name and frequency. Count of participants reporting zolpidem or trazodone use for sleep is recorded for adherence to the Medication and Combination treatment arms.

Time frame:
1 month, 9 weeks, 6 months, 9 months, 12 months
Reported as:
Count of participants · Participants
Medication Adherence
ParticipantsMedication (Zolpidem or Trazodone)Combination
Medication Adherence3828
Other pre-specifiedSelf-reported Falls

Participants self-reported number of falls including context, location, and consequences of falls. Count of participants with one or more falls up through the 6 month follow-up.

Time frame:
1 month, 9 weeks, 6 months
Reported as:
Count of participants · Participants
Self-reported Falls
ParticipantsMedication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)Combination
Self-reported Falls837

Adverse events

Collected over 12 months. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Medication (Zolpidem)0/11 (0%)1/11 (9.1%)4/11 (36.4%)
Medication (Trazodone)0/38 (0%)0/38 (0%)10/38 (26.3%)
Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)0/54 (0%)2/54 (3.7%)6/54 (11.1%)
Combination (Zolpidem)0/11 (0%)0/11 (0%)2/11 (18.2%)
Combination (Trazodone)0/41 (0%)0/41 (0%)7/41 (17.1%)
Most frequent serious events
Most frequent serious events
EventMedication (Zolpidem)Medication (Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)Combination (Zolpidem)Combination (Trazodone)
Urinary tract infectionInfections and infestations1/110/380/540/110/41
SomnolenceNervous system disorders0/110/381/540/110/41
EpistaxisRespiratory, thoracic and mediastinal disorders0/110/381/540/110/41
Most frequent other events
Most frequent other events
EventMedication (Zolpidem)Medication (Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)Combination (Zolpidem)Combination (Trazodone)
DizzinessNervous system disorders2/110/380/540/111/41
SomnolenceNervous system disorders1/116/385/542/113/41
FallInjury, poisoning and procedural complications1/112/382/540/114/41
PalpatationsCardiac disorders1/110/380/540/110/41
ArthritisMusculoskeletal and connective tissue disorders1/110/380/540/110/41
HeadacheNervous system disorders1/112/380/540/111/41
ConfusionNervous system disorders1/110/380/540/110/41

Baseline characteristics

Age, Continuous
Age, Continuous(years)Medication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)CombinationTotal
Mean55.2 ± 14.652.5 ± 15.352.5 ± 15.353.4 ± 15.0
Sex: Female, Male
Sex: Female, Male(Participants)Medication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)CombinationTotal
Female374437118
Male12101436
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Medication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)CombinationTotal
Hispanic or Latino1034
Not Hispanic or Latino485449151
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Medication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)CombinationTotal
American Indian or Alaska Native0000
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American0314
White474949145
More than one race1102
Unknown or Not Reported1023
Region of Enrollment
Region of Enrollment(participants)Medication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)CombinationTotal
United States495452155
Medication preference
Medication preference(Participants)Medication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)CombinationTotal
Zolpidem11101132
Trazodone384441123
Insomnia Severity Index total score
Insomnia Severity Index total score(score on a scale)Medication (Zolpidem or Trazodone)Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)CombinationTotal
Mean18.1 ± 4.317.4 ± 3.718.9 ± 4.218.1 ± 4.1
08

Study locations

7 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • University of Arizona
    Tucson, Arizona 85721, United States
  • University of Missouri
    Columbia, Missouri 65212, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • University of Virginia
    Charlottesville, Virginia 22908, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Jun 2024, 28 months.

Results were first posted in Feb 2025, 7 months after primary completion.

Of 53 non-industry phase 4 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 59. This study's 28 months is close to that.

Counting every sponsor, half of 58 studies reached it within 28 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2020
First posted
Jul 13, 2020
StartActual
Feb 25, 2022
Primary completionActual
Jun 30, 2024
CompletionActual
Jun 30, 2024
Results first posted
Feb 24, 2025
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04468776
Lead sponsor
California Pacific Medical Center Research Institute
Responsible party
Sponsor
First posted
Jul 13, 2020
Start date
Feb 25, 2022
Primary completion
Jun 30, 2024
Completion
Jun 30, 2024
Results posted
Feb 24, 2025
Last update
Feb 24, 2025

Study contacts

Katie L. Stone, PhD
principal investigator · California Pacific Medical Center/Sutter Bay Hospitals
Daniel J. Buysse, MD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zolpidem · Trazodone

Start the discussion